Cardiac, Neuropsychiatric Events With ADHD Drugs To Be Discussed By Pediatric Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's Pediatric Advisory Committee will address neuropsychiatric and cardiovascular events possibly related to attention deficit/hyperactivity disorder medications at a March 22 meeting
You may also be interested in...
ADHD Individual Drug Risk Studies To Be Considered By Drug Safety Committee
FDA to present analysis of sudden death and serious cardiovascular event rates with amphetamine and methylphenidate products at Feb. 9 meeting of Drug Safety & Risk Management Advisory Committee.
ADHD Individual Drug Risk Studies To Be Considered By Drug Safety Committee
FDA to present analysis of sudden death and serious cardiovascular event rates with amphetamine and methylphenidate products at Feb. 9 meeting of Drug Safety & Risk Management Advisory Committee.
Cephalon Sparlon For ADHD To Get Psychopharm Committee Review
The March 23 review of the new indication for modafinil, currently marketed as Provigil for narcolepsy, will likely focus on safety differences compared to other ADHD drugs.